Rhythm Pharmaceuticals announced three late-breaking abstracts accepted for presentation at ENDO 2025, highlighting new research on acquired hypothalamic obesity treatments.
Quiver AI Summary
Rhythm Pharmaceuticals, a biopharmaceutical company focused on rare neuroendocrine diseases, announced the acceptance of three late-breaking abstracts for presentation at The Endocrine Society’s Annual Meeting (ENDO 2025) from July 12-15 in San Francisco. Key presentations will include a live oral session by Dr. Susan Phillips on data from the Phase 3 TRANSCEND trial evaluating the drug setmelanotide for acquired hypothalamic obesity, along with poster presentations by Dr. Christian Roth on patient experiences during the trial and Dr. Vidhu Thaker on a Phase 2 trial of the oral drug bivamelagon. Rhythm's ongoing commitment includes advancing therapies for rare diseases, with setmelanotide already approved for certain obesity conditions in the U.S. and Europe. The company aims to transform the lives of patients and will provide access to all related conference materials following the event.
Potential Positives
- Three late-breaking abstracts accepted for presentation at ENDO 2025 highlight Rhythm Pharmaceuticals' commitment to advancing research in neuroendocrine diseases.
- Data from the pivotal Phase 3 TRANSCEND trial of setmelanotide will be presented, showcasing the company's significant clinical advancements in treating acquired hypothalamic obesity.
- Presence at a major medical conference enhances the company's visibility and credibility within the healthcare and scientific communities.
Potential Negatives
- The press release includes multiple warnings and precautions regarding serious side effects associated with Rhythm's lead product, IMCIVREE® (setmelanotide), raising concerns about patient safety.
- There is a stark limitation of use for setmelanotide, which could restrict potential market size and patient population, as the drug is not indicated for various types of obesity.
- The acknowledgment of forward-looking statements may indicate inherent uncertainties and risks, which could potentially affect investor confidence and the company's financial stability.
FAQ
What will Rhythm Pharmaceuticals present at ENDO 2025?
Rhythm Pharmaceuticals will present three late-breaking abstracts regarding their clinical trials on setmelanotide and bivamelagon for obesity.
Who will present the data from the TRANSCEND trial?
Dr. Susan Phillips from UC San Diego will present data from Rhythm’s pivotal Phase 3 TRANSCEND trial on July 12, 2025.
What are the main indications for setmelanotide?
Setmelanotide is indicated for reducing body weight in patients with syndromic or monogenic obesity due to specific genetic deficiencies.
When is the ENDO 2025 conference taking place?
ENDO 2025 is scheduled for July 12-15, 2025, in San Francisco, CA.
How can I access Rhythm's presentations after ENDO 2025?
All Rhythm-related presentations from ENDO 2025 will be available on their dedicated publication webpage after the conference.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RYTM Insider Trading Activity
$RYTM insiders have traded $RYTM stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.
Here’s a breakdown of recent trading of $RYTM stock by insiders over the last 6 months:
- YANN MAZABRAUD (EVP, Head of International) has made 0 purchases and 5 sales selling 99,495 shares for an estimated $5,382,716.
- DAVID W J MCGIRR has made 0 purchases and 2 sales selling 65,431 shares for an estimated $4,267,494.
- DAVID P MEEKER (President and CEO) has made 0 purchases and 4 sales selling 57,794 shares for an estimated $3,657,824.
- PAMELA J. CRAMER (Chief Human Resources Officer) has made 0 purchases and 10 sales selling 37,407 shares for an estimated $2,334,699.
- JENNIFER KAYDEN LEE (EVP, Head of North America) has made 0 purchases and 13 sales selling 14,784 shares for an estimated $866,161.
- HUNTER C SMITH (Chief Financial Officer) has made 0 purchases and 6 sales selling 5,940 shares for an estimated $343,345.
- JOSEPH SHULMAN (Chief Technical Officer) has made 0 purchases and 6 sales selling 3,772 shares for an estimated $218,510.
- CHRISTOPHER PAUL GERMAN (Corporate Controller & CAO) has made 0 purchases and 3 sales selling 3,048 shares for an estimated $194,005.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RYTM Hedge Fund Activity
We have seen 134 institutional investors add shares of $RYTM stock to their portfolio, and 106 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,575,266 shares (+1392.7%) to their portfolio in Q1 2025, for an estimated $83,441,840
- WESTFIELD CAPITAL MANAGEMENT CO LP added 1,341,092 shares (+inf%) to their portfolio in Q1 2025, for an estimated $71,037,643
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,191,048 shares (-63.7%) from their portfolio in Q1 2025, for an estimated $63,089,812
- PERCEPTIVE ADVISORS LLC removed 1,132,028 shares (-30.8%) from their portfolio in Q1 2025, for an estimated $59,963,523
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND removed 1,111,043 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $62,196,187
- POLAR CAPITAL HOLDINGS PLC removed 1,000,000 shares (-66.7%) from their portfolio in Q1 2025, for an estimated $52,970,000
- PRIMECAP MANAGEMENT CO/CA/ removed 783,868 shares (-11.9%) from their portfolio in Q1 2025, for an estimated $41,521,487
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RYTM Analyst Ratings
Wall Street analysts have issued reports on $RYTM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 03/18/2025
- Jefferies issued a "Buy" rating on 12/31/2024
To track analyst ratings and price targets for $RYTM, check out Quiver Quantitative's $RYTM forecast page.
$RYTM Price Targets
Multiple analysts have issued price targets for $RYTM recently. We have seen 2 analysts offer price targets for $RYTM in the last 6 months, with a median target of $79.0.
Here are some recent targets:
- An analyst from Stifel Nicolaus set a target price of $78.0 on 03/05/2025
- Dennis Ding from Jefferies set a target price of $80.0 on 01/01/2025
Full Release
BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three late-breaking abstracts have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
In a live oral presentation, Susan Phillips , M.D., Pediatric Endocrinology, University of California San Diego/Rady Children’s Hospital, San Diego, will present data from Rhythm’s pivotal Phase 3 TRANSCEND trial evaluating setmelanotide in the largest randomized, placebo-controlled trial in acquired hypothalamic obesity to date.
-
Efficacy and Safety of Setmelanotide in Acquired Hypothalamic Obesity: Results from a Double-Blind, Multicenter, Placebo-Controlled, Randomized Phase 3 Trial
July 12, 2025, 2:00 PM - 2:15 PM PT
Christian Roth, M.D., Seattle Children’s Research Institute, will present a poster detailing exit interviews gathered from 30 patients or caregivers located in the US with acquired hypothalamic obesity who participated in the Phase 3 TRANSCEND trial.
-
Experiences and Observations with Acquired Hypothalamic Obesity: A Qualitative Interview Sub-Study
July 14, 2025,12:00 PM - 1:30 PM PT
Vidhu Thaker, M.D., Pediatric Endocrinology, Columbia University, New York City will present a poster from the 14-week, multicenter, international, randomized, double-blind, placebo-controlled Phase 2 trial of bivamelagon, an oral MC4R agonist (formerly LB54640), in participants with acquired hypothalamic obesity.
-
Efficacy and Safety of Once-Daily Oral Bivamelagon in Acquired Hypothalamic Obesity: Results from a Double-blind, Multicenter, Placebo-Controlled, Randomized Phase 2 Trial
July 12 2025, 12:15 PM - 1:45 PM PT
All of the Rhythm-related presentations from ENDO 2025 will be available here following the conference: https://hcp.rhythmtx.com/publications-presentations/ .
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Setmelanotide Indication
In the United States
,
setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in
POMC
,
PCSK1
, or
LEPR
genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign
-
Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.
Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.
Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.
USE IN SPECIFIC POPULATIONS
Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full Prescribing Information for additional Important Safety Information.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the safety, efficacy, potential benefits of, and regulatory and clinical progress, potential regulatory submissions, approvals and timing thereof of setmelanotide and other product candidates; the clinical design or progress of any of our products or product candidates at any dosage or in any indication, the planned substudy to evaluate patients with congenital hypothalamic obesity and the timing of enrollment for the substudy to our Phase 3 trial evaluating setmelanotide in patients with acquired hypothalamic obesity; the potential benefits of any of the Company’s products or product candidates for any specific disease indication or at any dosage, including the potential benefits of setmelanotide for patients with acquired hypothalamic obesity or congenital hypothalamic obesity; the potential benefits of and the results from the Phase 2 Trial of bivamelagon in acquired hypothalamic obesity; our participation in upcoming events and presentations, and the date, time and content thereof and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
[email protected]
Media Contact:
Layne Litsinger
Real Chemistry
(410) 916-1035
[email protected]